Biotech News

Annovis Receives Second Positive DSMB Recommendation for its Phase 3 DUET-AD Study

Annovis Bio (ANVS)Annovis BioClinical readout

Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing buntanetap, an investigational once-daily pill for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced an independent Data and Safety Monitoring Board (DSMB) has issued its second consecutive positive recommendation for DUET-AD, the Company’s pivotal Phase 3 trial in early AD, after the review of the study’s safety data. This 12-month review follows the DSMB’s positive 6-month feedback, which was announced in February 2026 .

Related news

ANVSAnnovis Bio2026-10-30 21:00 EST

Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE

ANVSAnnovis Bio2026-11-12 13:00 EST

Annovis Bio Granted U.S. Patent Covering New Crystalline Form of Buntanetap

VTGNVistagen Therapeutics, Inc.2026-09-22 12:30 EST

Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

ALKSAlkermes plc2026-09-21 11:00 EST

Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

ABOSAcumen Pharmaceuticals2026-10-30 11:00 EST

Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint

XENEXenon2026-10-29 12:30 EST

Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain

ANNXAnnexon, Inc.2026-09-24 12:00 EST

Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting

ACIUAC Immune2026-09-23 11:00 EST

AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104

TEVATeva Pharmaceutical Industries2026-11-02 13:00 EST

Teva to Discontinue Phase 2 TOPAS-MSA Study of emrusolmin (TEV-‘286) Following Interim Futility Analysis

ANNXAnnexon, Inc.2026-10-28 12:01 EST

Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial

Annovis Bio

Phase 3 Neurodegenerative Disease Company Annovis Bio is developing buntanetap, an oral candidate for Alzheimer’s disease and Parkinson’s disease. Through an RNA-targeting mechanism, buntanetap is designed to reduce translation of multiple neurotoxic proteins, including APP/amyloid beta, tau, alpha-synuclein, and TDP-43. Registrational...

Recent company news

Stock data

Close
0.75 USD
Market cap
79.13M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States